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http://dx.doi.org/10.1016/j.jmii.2012Background: Candida empyema thoracis is a serious complication of invasive candidiasis with
high mortality. However, the treatment for Candida empyema remains controversial. We con-
ducted a 9-year retrospective study to analyze the treatments and factors associated with the
mortality of patients with Candida empyema thoracis in two medical centers in central
Taiwan.
Methods: The medical records of all patients with positive Candida culture from pleural effu-
sion between October 2002 and September 2011 were reviewed. The demographic data, treat-
ment regimens, and factors associated with mortality were analyzed.
Results: During the period of this study, 102 patients were identified. Sixty-three of these
patients fulfilled the enrollment criteria, and their data were analyzed. Three-quarters of
these patients were male, and the median age of these patients was 69. Thirty-five (55.6%)
patients had contiguous infection. The crude mortality rate was 61.9%. Candida albicans
was the most common isolate, and malignancy was the most common underlying disease.
Patients with advanced age, a higher Charlson’s score, shock status, respiratory failure, and
noncontiguous infection had a higher mortality rate. Those who had received surgical interven-
tion had a better outcome. In multivariate analysis, the shock status, respiratory failure, and
noncontiguous infection source were associated with a higher mortality risk.Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, Number 2,
om (C.-Y. Chi), cmchid@yahoo.com.tw (M.-W. Ho).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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rate. Shock status, respiratory failure, and noncontiguous infection were factors associated
with a higher mortality rate. Surgical intervention or drainage may improve the treatment
outcome, especially in patients with contiguous infection.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Invasive candidiasis has emerged as an important nosoco-
mial infection, especially in critical patients. The most
common invasive candidiasis is candidemia and the inci-
dence of nosocomial candidemia has increased in the past
few decades.1,2 Fungal empyema thoracis is a rare but
severe invasive candidiasis with high mortality, and Candida
species are the most frequent isolates.3 There are several
mechanisms of empyema thoracis, including infection of the
pleural cavity, thoracotomy, trauma, esophageal rupture,
subdiaphragmatic spread, and hematogenous seeding.3,4
Treatment options for Candida empyema thoracis, regard-
less of the mechanism, include antifungal therapy, tubal
drainage, tubal irrigation, fibrinolytic therapy, and surgical
intervention.3,5,6 However, despite the high mortality rate
of Candida empyema, the treatment for Candida empyema
thoracis remains controversial.3 There has been no large
series of Candida empyema thoracis reports in the past 10
years. Therefore, we conducted this retrospective study in
two medical centers in central Taiwan to analyze the
treatments and factors associated with the mortality of
patients with Candida empyema thoracis.
Materials and methods
Patients and settings
During the period from October 2002 to September 2011, all
patients treated at the China Medical University Hospital
(CMUH; a 2000-bed teaching hospital in Taichung City,
central Taiwan) and Changhua Christian Hospital (CCH;
a 1600-bed teaching hospital in Changhua City, central
Taiwan) with a positive culture of Candida spp. from pleural
effusion were included. The medical charts were thor-
oughly reviewed and the demographic data, predisposing
factors, underlying disease (including malignancy, dia-
betes, uremia, heart failure, and cirrhosis), Charlson’s
score (used as a composite index of comorbidities), clinical
features, laboratory data, treatments, and outcomes were
collected. The association of variables with the mortality of
patient with Candida empyema thoracis was analyzed.
Inclusion criteria
Only patients with conditions fitting the diagnostic criteria of
Candida empyema thoracis during study period were
included. The diagnostic criteria of Candida empyema thora-
cis was modified according to that proposed by Ko et al3: (1)
isolation of a Candida species from an exudative pleuraleffusion; (2) significant signs of infection, such as fever (body
temperature>38.3Cor<36C)and leukocytosis (whiteblood
cells >10,000/mL) or leucopenia (white blood cells <1000/
mL); and (3) isolation of the same Candida species from
pleural effusion on more than one occasion, or from pleural
effusion and blood. Candida isolated from prior tube thora-
cotomy for preexisting pneumothorax or bacterial empyema
were assumed to be colonized within the chest tubes, unless
the infection persisted without antifungal therapy.
Definitions
The definitions of an appropriate antibiotic treatment was
defined as using antibiotics, to which the bacteria isolates
were in vitro sensitive, within 72 hours after the diagnosis of
empyema was made. All-cause in-hospital mortality was
defined as all deaths that occurred during hospitalization
after theonsetofCandidaempyema thoracis.Thepathogenic
mechanisms of Candida empyema thoracis were divided into
two categories: contiguous infection for empyema in patients
who had adjacent infection, such as esophageal rupture,
pneumonia, mediastinitis, paraspinal abscess, or sub-
diaphragmatic liver abscess; and noncontiguous infection for
empyema in patients who had a distant infection focus, such
as intra-abdominal abscess, ischemic bowel, bowel perfora-
tion or fungemia, or an unidentified infection source.
Microbiology identification
The pleural fluid collected by thoracentesis or during tube
thoracotomy were streaked over trypticase soy agar (TSA)
with 5% sheep blood (TSA II/Levine eosin methylene blue
agar; Becton Dickinson, Franklin Lakes, NJ, USA) and incu-
bated at 35 C. Blood culture was processed initially by the
BACTEC 9000 system (Becton Dickinson). Positive bottles
were subcultured onto TSA II/Levine eosin methylene blue
agar and incubated at 35C. Isolates were identified as
various Candida spp. by Gram stain, CHROMagar culture
(Becton Dickinson), and the ID 32 C (bioMerieux SA, Marcy
l’Etoile, France) system for yeast. The sensitivity test was
performed using the ATB FUNGUS 3 system. The sensi-
tivity test, however, was not performed at CCH, which was
the only difference between the methods employed for
microbiological identification by the two hospitals.
Statistical analysis
Normally distributed continuous variables were reported as
mean standard deviation (SD) andwere compared using the
independent Student’s t-test. Medians with ranges were used
Table 1 Demographic data and clinical characteristics of
patients with Candida empyema thoracis
Survival
(%)
Mortality
(%)
p
Total patient number, n (%) 24 (38.1) 39 (61.9)
Age (y), mean  SD 59  17 70  13 0.042
Male, n (%) 17 (71) 29 (74.4) 0.78
Charlson’s score, median
(range)
3 (0e8) 4 (1e11) 0.03
Clinical manifestations
Shock, n (%) 4 (16.7) 28 (71.8) <0.01
Respiratory failure, n (%) 12 (50) 36 (92.3) <0.01
Dyspnea, n (%) 18 (75) 35 (89.7) 0.16
Fever, n (%) 17 (71) 24 (61.5) 0.59
Chest pain, n (%) 10 (41.7) 8 (20.5) 0.09
Fungemia, n (%) 1 (4.2) 8 (20.5) 0.13
Concomitant bacterial
infection, n (%)
11 (45.8) 20 (51.3) 0.80
Underlying disease
Malignancy, n (%) 11 (45.8) 18 (46.2) 1.00
Diabetes mellitus, n (%) 6 (25) 10 (25.6) 1.00
Uremia, n (%) 3 (12.5) 7 (17.9) 0.73
Congestive heart failure,
n (%)
2 (8.3) 7 (17.9) 0.46
Liver cirrhosis, n (%) 1 (4.2) 5 (12.8) 0.40
Chronic obstructive
pulmonary disease
1 (4.2) 4 (10.2) 0.64
Pathogenic mechanism
Contiguous infection, n (%) 19 (79.2) 16 (41) 0.004
Noncontiguous infection,
n (%)
5 (20.8) 23 (59)
Treatment
With antifungal agents, n (%) 20 (83.3) 24 (61.5) 0.10
Duration of antifungal
agents, median (range)
15 (7e26) 14 (1e39)
With interventions, an (%) 22 (91.7) 26 (66.7) 0.03
With appropriate
antibacterial antibiotics
10(41.7) 15 (38.5) 0.37
Outcome
From culture day to
death, median (range)
e 11 (1e95)
a Interventions include surgical treatment, tubal drainage,
tubal irrigation, and fibrinolytic irrigation.
SD Z standard deviation.
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were compared using the ManneWhitney U-test. Categorical
variables were analyzed with proportions and were compared
using the chi-square test. A p value of 0.05 was considered
statistically significant, and all tests for significancewere two-
tailed.A logistic regressionmodelwasapplied formultivariate
analysis to determine theprognostic influence of the variables
on mortality. Statistical analyses were performed using the
Statistical Package for the Social Sciences (SPSS) for Windows
(Version 18.0; SPSS, Inc., Chicago, IL, USA).
Results
Clinical characteristics and manifestations
Between October 2002 and September 2011, 102 patients
with Candida species isolated from pleural fluid were
identified. Thirty-nine patients were excluded due to at
least one of the following conditions: (1) the pleural effu-
sion was transudate (n Z 8); (2) the patient had no symp-
toms or signs of infection (n Z 5); and (3) the Candida
species was isolated from the existing tubal thoracotomy
(n Z 26), which was considered a colonizer using the
criteria described above. The data of the remaining 63
patients were further analyzed.
The demographic data, clinical manifestation, treatment,
and outcome are displayed in Table 1. Of these enrolled
patients, more than half were over 65 years old, and they had
a higher mortality than those younger than 65 years (68.4% vs.
52%, pZ 0.042). Three-quarters of the patients with Candida
empyema were male, but they had a similar mortality rate to
that of the female patients (63% vs. 58.8%, pZ 0.78). Patients
who survived this infection had a longer hospital stay.
Furthermore, three-quarters (nZ 47) of the patients needed
intensive care unit care. Patients with a higher Charlson’s
score had poorer outcomes (p Z 0.03). Most patients pre-
sented respiratory symptoms including chest pain, dyspnea,
and respiratory failure, and half of them had a shock status.
Patients who presented respiratory failure (p < 0.01) or had
a shock status (p < 0.01) bore higher risk for mortality. In
laboratory tests, most patients had an abnormal blood cells
count and a C-reactive protein level over 5 mg/dL (data not
shown). Themedianwhite blood cell count of pleural effusion
is 13,650 cells/mL, and the median red blood cell count is
18,500 cells/mL. About half of the enrolled patients had
bacterial coinfection in empyema (46%). Malignancy was the
most commonly encountered underlying disease (29 patients,
46%). The three most frequently encountered types of malig-
nancy were esophageal cancer (12 patients), gastric cancer (4
patients), and breast cancer (3 patients). Only nine (14.3%)
patients did not have an underlying comorbidity. Candida
empyema thoracis due to contiguous infection was more
common than those due to noncontiguous infection (55.6% vs.
44.4%). Patients with contiguous infection had a lower
mortality rate than thosewith noncontiguous infection (45.7%
vs. 82.1%, pZ 0.004).
Microbiology
Candida albicans was the most common isolated species (49
isolates, 76.5%), followed by C. tropicalis (seven isolates,10.9%), then C. glabrata (three isolates, 4.6%) (Table 2).
The isolated strains whose sensitivity test was performed at
the CMUH included 22 strains of C. albicans, three of C.
tropicalis, one of C. guilliemondii, and one of C. glabrata.
The sensitivity result revealed that all isolates were sensi-
tive to fluconazole, apart from the C. glabrata isolate,
whose fluconazole minimal inhibitory concentration (MIC)
was 4.0 mg/mL. For bacteria concomitantly isolated from
pleural effusion, Pseudomonas aeruginosa was the most
common isolated pathogen (12 isolates), followed by
Klebsiella pneumoniae (8 isolates), Enterococcus faecalis
(5 isolates), Escherichia coli (4 isolates), Enterobacter
cloacae (3 isolates), and Acinetobacter baumannii (2
isolates). Streptococcus species was cultured in eight
specimens.
Table 3 Factors associated with mortality in patients with
Candida empyema thoracis: multivariate analysis
Mortality
Odds
ratio
95% confidence
interval
p
Age 1.03 0.97e1.09 0.30
Male 3.52 0.50e24.52 0.20
Charlson
Comorbidity
Index
1.29 0.91e1.81 0.14
Shock 6.43 1.19e34.69 0.03
Respiratory failure 26.00 1.99e339.16 0.01
Contiguous infection 0.03 0.003e0.41 0.008
Table 2 Candida species isolated from pleural fluid
Candida isolates Number of isolatesa (%)
C. albicans 49 (76.5)
C. tropicalis 7 (10.93)
C. glabrata 3 (4.68)
C. famata 2 (3.12)
C. intermedia 1 (1.56)
C. guilliermondii 1 (1.56)
C. melibiosica 1 (1.56)
a Sixty-three patients with 64 isolates, one patient with two
isolates of C. tropicalis and C. glabrata in pleural effusion.
Candida empyema thoracis 39Treatment and outcome
Forty-four patients received antifungal treatment ranging
from 1 to 39 days, with a median duration of 15 days. One
patient received anidulafungin as the initial treatment for
C. albicans empyema, while 43 others received fluconazole
initially. One of these 43 patients shifted regimen to
amphotericin B plus flucytosine; another individual shifted
to caspofungin; and yet another one shifted to voriconazole
according to the clinician’s judgment. Of the 44 patients
who received antifungal agent treatment, 24 (54.5%) died
(p Z 0.1).
Regarding invasive procedures, 12 patients received
surgical treatment, 48 patients received tubal drainage,
and two patients received fibrinolytic therapy. Seven
(11.1%) patients received no antifungal treatment,
drainage, or surgical intervention. Patients who received
surgical or drainage intervention had a lower mortality rate
than those who did not (54.2% vs. 86.7%, p Z 0.03). All
seven patients who received no treatment for Candida
empyema thoracis died. Among the total of 63 patients
with Candida empyema, 39 died. The crude mortality rate
was 61.9%. The median interval between the diagnosis of
Candida empyema and death was 11 days. Of the three
patients with C. glabrata isolated from their pleural fluid,
two died. These three patients all received intravenous
fluconazole for the treatment of Candida empyema thora-
cis. However, the one who survived had a contiguous
infection and received surgical intervention, while the
other two had a noncontiguous infection and did not
receive invasive drainage procedure. Thirty-one patients
had concomitant bacterial pleural infection. Twenty-five
patients received appropriate antibiotics treatment and
15 of them (60%) died, and in the other six patients who did
not receive appropriate antibiotics treatment, five (83.3%)
died (p Z 0.37).
Multivariate analysis
Multivariate logistic regression analysis was performed. All
variants significantly associated with mortality found in
univariate analysis were drawn into the analysis. The result
of multivariate analysis revealed that shock status
(p Z 0.03), respiratory failure (p Z 0.01), and noncontig-
uous infection (p < 0.01) were independent risk factors for
the mortality of patients with Candida empyema thoracis
(Table 3).Discussion
Male patients accounted for a higher proportion than
female patients in Candida empyema. This may be due to
the high percentage of patients with esophageal cancer or
gastric cancer, which are male-dominant diseases in
Taiwan. The median interval from the culture day to death
is only 11 days, which may explain why those patients who
survived this infection had a longer hospitalization period
or intensive care unit stay.
The major causes of reported cases of fungal empyema
thoracis include esophageal perforation, abdominal infec-
tion, bronchopulmonary infection, surgical intervention,
and repeated thoracentesis.3,6e9 More than half of our
patients had Candida empyema thoracis with a gastroin-
testinal origin, which may explain why the most common
fungal pathogen isolated from pleural effusion was C.
albicans. This supports the finding that the isolation of
Candida species can be an important clue for suspecting
gastrointestinal tract perforation, as proposed by Ishiguro
et al.6 Furthermore, in this study, we discovered that the
hematogenous spread of Candida into the pleural space
may also be an important infection route in the noncon-
tiguous infection group, and the patients with this route of
infection had poorer outcomes.
Many factors have been reported to be associated with
the mortality of patients with candidemia including
advanced age, septic shock, non-albicans candidemia, and
a high severity of the disease.10e12 For patients with fungal
empyema, immunocompromised status and respiratory
failure were reported to be associated with mortality, and
systemic antifungal therapy was associated with a lower
risk of death.3 In our study, patients with advanced age
(>65 years), a higher Charlson’s score, a noncontiguous
infection, a shock status, respiratory failure, or no inter-
vention had a higher risk of mortality according to the
univariate analysis. In multivariate logistic regression
analysis, only shock status, respiratory failure, and
noncontiguous infection were significantly associated with
the risk of mortality. Shock status and respiratory failure
reflect the severity of the disease and their association with
mortality is logically reasonable. However, the higher
mortality rate of patients with noncontiguous infection has
never been mentioned before. In our study, patients who
received drainage (surgical or tubal) had a lower mortality
40 K.-H. Lin et al.rate than those who did not (54.2% vs. 86.7%, p Z 0.03),
although it was not significant in the multivariate analysis.
A similar difference was also highlighted in Ko et al’s3 study
(66% vs. 87%, with and without drainage). In another
previous study, patients who did not receive antifungal
therapy were reported to have survived from Candida
empyema thoracis due to GI tract rupture with only
drainage and antibiotics.6 Therefore, we believe that
surgical intervention with adequate drainage could consti-
tute an essential treatment for patients with Candida
empyema thoracis. After comparing the clinical data, it was
found that the patients’ clinical conditions were similar in
both contiguous and noncontiguous infection groups,
except for the fact that more patients received surgical
intervention or drainage in the contiguous infection group
(88.6% vs. 60.7%). So the higher percentage of patients
receiving surgical intervention in the contiguous infection
group could lead to the lower mortality rate in this group,
and this finding could also explain why, of the three
patients with C. glabrata empyema, only the patient who
had received surgical intervention survived.
A possible reason surgical intervention is more effective
than a systemic antifungal agent is that the concentration
of antifungal agents in pleural fluid is variable. Vor-
iconazole and micafungin have been reported to provide
good pleural penetration and successful treatment for
Aspergillus empyema.13,14 Anidulafungin and liposomal
amphotericin B, in contrast, were reported to have poor
pleural concentration and a low pleura/serum concentra-
tion ratio, and tubal drainage is warranted for successful
treatment.15e17 Data on the concentration of fluconazole,
the agent used most frequently to treat Candida empyema
thoracis in our study, in pleural effusion are lacking, and it
remains uncertain whether the pleural effusion concen-
tration of fluconazole influenced the success rate of the
treatment of Candida empyema thoracis in this study.
Further studies investigating the association between the
concentration of antifungal agents in pleural fluid and the
treatment outcome are warranted.
Another reason for the improved outcomes of the
patients in contiguous infection group may be the localized
infection in nature, which may respond to adequate
debridement and drainage. In contrast, Candida empyema
thoracis from a noncontiguous infection source was
supposed to spread hematogenously, and an early systemic
antifungal agent treatment is essential for treating
systemic fungal infection. Because of the suspected
hematogenous route of infection, we have tried to figure
out if eradication of other infection focus, such as central
catheter, would improve mortality rate. Removal of central
venous catheter (CVC) was only performed in a few patients
with candidemia in CMUH, however, and no removal was
performed in all 29 CCH patients. For the nine patients with
candidemia in this study, seven patients had CVC place-
ment and three of them had removal of CVC. After analysis,
the correlation between catheter removal and mortality
was not significant (p Z 0.606). However, the sample size
might be too small to make this result meaningful.
There are several limitations to our study. First, our
sample size is small, which may render some potentially
influential parameters insignificant, such as antibacterial
antibiotic therapy and interventions in multivariateanalysis. Second, because this is a retrospective study, it
was impossible to identify whether the improved outcome
of the contiguous infection group was caused by the
increased surgical intervention, the localized infection
itself, or both. Third, because the sensitivity test for
Candida species isolated from CCH is not routinely per-
formed, and it was not performed for all Candida species
isolated from CMUH, we could not totally exclude the
possibility that strains resistant to antifungal agents existed
and could not be sure if all antifungal agents were active to
the isolates. This resistance might also contribute to the
failure of treatment for Candida empyema thoracis.
Fourth, also because this study is retrospective, other
manifestations of systemic involvement, such as eye ground
involvement or liver/spleen involvement, could not be
evaluated if the examination was not performed when
Candida empyema thoracis was diagnosed. Also, the effect
of eradicating pathogens from infection sites other than
pleural space, such as ophthalmic debridement or abscess
drainage, could not be evaluated in this study.
In conclusion, Candida empyema thoracis is a severe
invasive candidiasis with a mortality rate as high as 61.9%.
Patients with shock status and respiratory failure were
associated with a higher mortality rate, and those with
empyema due to contiguous infection had better outcomes.
As to antifungal therapy, micafungin and voriconazole were
reported with good pleural fluid concentration and
successful treatment, but data on the pleural concentra-
tion of fluconazole are lacking, and its treatment efficacy
for Candida empyema thoracis remains undetermined.
Finally, we conclude that surgical treatment and adequate
drainage are essential for Candida empyema, especially in
patients with contiguous infection.
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